Interferon (alpha, beta and omega) receptor 2 is a prognostic biomarker for lung cancer

Pathobiology

Volumn 79, Issue 1, 2012, Pages 24-33

  Tanaka, Sonosuke ^a   Hattori, Noboru ^a   Ishikawa, Nobuhisa ^a   Horimasu, Yasushi ^a   Deguchi, Naoko ^a   Takano, Atsushi ^a   Tomoda, Yoshitaka ^a   Yoshioka, Koji ^a   Fujitaka, Kazunori ^a   Arihiro, Koji ^a   Okada, Morihito ^a   Yokoyama, Akihito ^b   Kohno, Nobuoki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KOCHI UNIVERSITY   (Japan)

Author keywords

Biomarker; Cell surface antigen; Interferon (alpha, beta and omega) receptor 2; Lung cancer

Indexed keywords

BIOLOGICAL MARKER; INTERFERON (ALPHA,BETA AND OMEGA) RECEPTOR 2; INTERFERON RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LUNG CANCER; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, INTERFERON ALPHA-BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 84855871242     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000331230     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statis-tics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Ad-jei AA: Non-small cell lung cancer: epidemi-ology, risk factors, treatment, and survivor-ship. Mayo Clin Proc 2008; 83: 584-594. (Pubitemid 351720831)
3. Pérez-Soler R: Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Oncogene 2009; 28:S38-S45.
4. Amelung JT, Bührens R, Beshay M, Rey-mond MA: Key genes in lung cancer transla-tional research: a meta-analysis. Pathobiology 2010; 77: 53-63.
5. Daigo Y, Nakamura Y: From cancer genom-ics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinomas. Gen Thorac Cardiovasc Surg 2008; 56: 43-53. (Pubitemid 351311467)
6. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K Yamakido M: Detection of sol-uble tumor-associated antigens in sera and effusions using novel monoclonal antibod-ies, KL-3 and KL-6, against lung adenocarci-noma. Jpn J Clin Oncol 1988; 18: 203-216.
7. Inata J, Hattori N, Yokoyama A, Ohshimo S, Doi M, Ishikawa N, Hamada H, Kohno N: Circulating KL-6/MUC1 mucin carrying sialyl Lewisa oligosaccharide is an indepen-dent prognostic factor in patients with lung adenocarcinoma. Int J Cancer 2007; 120: 2643-2649. (Pubitemid 46651286)
8. Ishikawa N, Hattori N, Yokoyama A, Tanaka S, Nishino R, Yoshioka K, Ohshimo S, Fuji-taka K, Ohnishi H, Hamada H, Arihiro K Kohno N: Usefulness of monitoring the cir-culating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced non-small cell lung cancer treated with epidermal growth factor receptor tyro-sine kinase inhibitors. Int J Cancer 2008; 122: 2612-2620. (Pubitemid 351590499)
9. Tanaka S, Hattori N, Ishikawa N, Shoda H, Takano A, Nishino R, Okada M, Arihiro K, Inai K, Hamada H, Yokoyama A, Kohno N: Krebs von den Lungen-6 (KL-6) is a prog-nostic biomarker in patients with surgically resected non-small cell lung cancer. Int J Cancer 2011, E-pub ahead of print.
10. Pitha PM: Introduction: interferon's connec-tion to cancer. Semin Cancer Biol 2000; 10: 69-72.
11. Borden EC: Review: Milstein Award lecture: interferons and cancer: where from here? J Interferon Cytokine Res 2005; 25: 511-527. (Pubitemid 41395839)
12. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR: Inter-ferons at age 50: past, current and future im-pact on biomedicine. Nat Rev Drug Discov 2007; 6: 975-990. (Pubitemid 350201788)
13. Theofilopoulos AN, Baccala R, Beutler B, Kono DH: Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307-336. (Pubitemid 40563172)
14. Yatsuhashi H, Fujino T, Matsumoto T, Inoue O, Koga M, Yano M: Immunohistochemical analysis of hepatic interferon alpha-beta re-ceptor level: relationship between receptor expression and response to interferon thera-py in patients with chronic hepatitis C. J Hepatol 1999; 30: 995-1003. (Pubitemid 29278742)
15. Fujiwara D, Hino K, Yamaguchi Y, Ren F, Sa-toh Y, Korenaga M, Okuda M, Okita K: He-patic expression of type I interferon receptor for predicting response to interferon therapy in chronic hepatitis C patients: a comparison of immunohistochemical method versus competitive polymerase chain reaction as-say. Hepatol Res 2003; 25: 377-384. (Pubitemid 36519284)
16. Takemoto Y, Yano H, Momosaki S, Ogasa-wara S, Nishida N, Kojiro S, Kamura T, Ko-jiro M: Antiproliferative effects of interfer-on-alphaCon1 on ovarian clear cell adeno-carcinoma in vitro and in vivo. Clin Cancer Res 2004; 10:7418-7426. (Pubitemid 39487731)
17. Eguchi H, Nagano H, Yamamoto H, Miya-moto A, Kondo M, Dono K, Nakamori S, Umeshita K, Sakon M, Monden M: Augmen-tation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocel-lular carcinoma cells. Clin Cancer Res 2000; 6:2881-2890. (Pubitemid 30482131)
18. Kondo M, Nagano H, Wada H, Damdin-suren B, Yamamoto H, Hiraoka N, Eguchi H, Miyamoto A, Yamamoto T, Ota H, Nakamu-ra M, Marubashi S, Dono K, Umeshita K Nakamori S, Sakon M, Monden M: Combi-nation of IFN-alpha and 5-fluorouracil in-duces apoptosis through IFN-alpha/beta re-ceptor in human hepatocellular carcinoma cells. Clin Cancer Res 2005; 11:1277-1286. (Pubitemid 40175781)
19. Ota H, Nagano H, Sakon M, Eguchi H, Kon-do M, Yamamoto T, Nakamura M, Damdin-suren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M: Treatment of hepatocellular carcinoma with major portal vein thrombo-sis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluoro-uracil; role of type 1 interferon receptor ex-pression. Br J Cancer 2005; 93: 557-564. (Pubitemid 43079999)
20. Ota H, Nagano H, Doki Y, Sekimoto M, Kon-do M, Wada H, Nakamura M, Noda T, Dam-dinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M, Monden M: Expression of type I interferon receptor as a predictor of clinical response to interferon-alpha therapy of gastrointestinal cancers. Oncol Rep 2006; 16:249-255.
21. Kamai T, Yanai Y, Arai K, Abe H, Yamanishi T, Kurimoto M, Yoshida K: Increased inter-feron alpha receptor 2 mRNA levels is associ-ated with renal cell carcinoma metastasis. BMC Cancer 2007; 7:159.
22. Hardy MP, Owczarek CM, Trajanovska S, Liu X, Kola I, Hertzog PJ: The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic proper-ties. Blood 2001; 97:473-482. (Pubitemid 32060333)
23. Ambrus JL Sr, Dembinski W, Ambrus JL Jr, Sykes DE, Akhter S, Kulaylat MN, Islam A, Chadha KC: Free interferon-alpha/beta re-ceptors in the circulation of patients with ad-enocarcinoma. Cancer 2003; 98:2730-2733. (Pubitemid 37509540)
24. Ito K, Tanaka H, Ito T, Sultana TA, Kyo T Imanaka F, Ohmoto Y, Kimura A: Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical re-sponse to interferon therapy in chronic my-elogenous leukemia. Eur J Haematol 2004; 73: 191-205. (Pubitemid 39062243)
25. Miyake K, Imura S, Nishioka M, Batmunkh E, Sugimoto K, Ohmoto Y, Shimada M: Se-rum evaluation of soluble interferon-alpha/ beta receptor and high-sensitivity C-reactive protein for diagnosis of the patients with gas-trointestinal and hepatobiliary-pancreatic cancer. Cytokine 2010; 49:251-255.
26. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E: Histological Typing of Lung and Pleural Tumors: World Health Organi-zation International Histological Classifica-tion of Tumors, ed 3. Berlin, Springer, 1999.
27. Sobin LH, Wittekind CH (eds): UICC TNM Classification of Malignant Tumors, ed 5. New York, Wiley, 1997.
28. Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Naka-mura Y: ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004; 10:8638-8670.
29. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S, Murakami H, Takeshima Y, Inai K Nishimura H, Tsuchiya E, Kohno N Nakamura Y: Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to ge fitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005; 65: 9176-9184. (Pubitemid 41507981)
30. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Tanaka S, Yasui W, Takeshima Y, Inai K Nishimura H, Tsuchiya E, Kohno N, Na-kamura Y: Characterization of SEZ6L2 cell-surface protein as a novel histochemical and prognostic marker for lung cancer. Cancer Sci 2006; 97:737-745. (Pubitemid 43983786)
31. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y: Cancer-testis anti-gen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic tar-get for lung and esophageal carcinomas. Cancer Res 2007; 67:11601-11611.
32. Takano A, Ishikawa N, Nishino R, Masuda K Yasui W, Inai K, Nishimura H, Ito H, Na-kayama H, Miyagi Y, Tsuchiya E, Kohno N Nakamura Y, Daigo Y: Identification of nec-tin-4 oncoprotein as a diagnostic and thera-peutic target for lung cancer. Cancer Res 2009; 69:6694-6703.
33. Mizukoshi E, Kaneko S, Kaji K, Terasaki S, Matsushita E, Muraguchi M, Ohmoto Y, Ko-bayashi K: Serum levels of soluble interferon alpha/beta receptor as an inhibitory factor of interferon in the patients with chronic hepa-titis C. Hepatology 1999; 30:1325-1331. (Pubitemid 29510875)
34. Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic path-ways. Science 2004; 305: 1163-1167. (Pubitemid 39100331)
35. Haura EB, Zheng Z, Song L, Cantor A, Bepler G: Activated epidermal growth factor recep-tor-Stat-3 signaling promotes tumor surviv-al in vivo in non-small cell lung cancer. Clin Cancer Res 2005; 11:8288-8294. (Pubitemid 41746939)
36. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545. (Pubitemid 32173595)
37. Seruga B, Zhang H, Bernstein LJ, Tannock IF: Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008; 8:887-899.